Karen Ferrante - HUTCHMED DRC Non-Executive Independent Director

HCM Stock  USD 16.85  0.20  1.20%   

Director

Dr. Karen Jean Ferrante, M.D., is NonExecutive Independent Director of the Company. Dr. Ferrante, has more than 20 years of experience in the pharmaceutical industry. She was the former Chief Medical Officer and Head of Research and Development of Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. From September 2007 to July 2013, Dr Ferrante held senior positions at Millennium Pharmaceuticals, Inc. and its parent company, Takeda Pharmaceutical Company Limited, including Chief Medical Officer and most recently as Oncology Therapeutic Area and Cambridge USA Site Head. From 1999 to 2007, she held positions of increasing responsibility at Pfizer Inc., with the last position as Vice President, Oncology Development. She began her career in the pharmaceutical industry in 1995 as Associate Director of Clinical Oncology at BristolMyers Squibb Company. For more than a decade prior to that, she was at the New England Deaconess Hospital in Boston, where she completed her internship and residency in internal medicine followed by her fellowship in hematology and oncology. since 2017.
Age 58
Tenure 7 years
Address Cheung Kong Center, Hong Kong, Hong Kong
Phone852 2121 8200
Webhttps://www.hutch-med.com

HUTCHMED DRC Management Efficiency

As of the 28th of March 2024, Return On Capital Employed is likely to grow to 0.02. Also, Return On Assets is likely to grow to 0.08. At this time, HUTCHMED DRC's Total Assets are very stable compared to the past year. As of the 28th of March 2024, Total Current Assets is likely to grow to about 1.2 B, while Non Currrent Assets Other are likely to drop about 11 M. HUTCHMED DRC's management efficiency ratios could be used to measure how well HUTCHMED DRC manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 86.13 M in debt. HUTCHMED DRC has a current ratio of 3.12, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist HUTCHMED DRC until it has trouble settling it off, either with new capital or with free cash flow. So, HUTCHMED DRC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like HUTCHMED DRC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for HUTCHMED to invest in growth at high rates of return. When we think about HUTCHMED DRC's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Robert HerboldAgilent Technologies
74
John FisherEquillium
60
Heidi KunzAgilent Technologies
66
Paul ClarkAgilent Technologies
72
Mark PruzanskiEquillium
50
Carina Olofsson23Andme Holding Co
42
Donald KufeMadrigal Pharmaceuticals
69
Daniel PodolskyAgilent Technologies
67
Dennis AusielloSeres Therapeutics
72
Martha DemskiEquillium
65
Meryl ZausnerSeres Therapeutics
61
Peter HuttSeres Therapeutics
80
Johannes Tiden23Andme Holding Co
34
Bo Eriksson23Andme Holding Co
65
Richard LevyMadrigal Pharmaceuticals
60
James DalyMadrigal Pharmaceuticals
N/A
Willard DereSeres Therapeutics
64
Tadataka YamadaAgilent Technologies
74
Werner CautreelsSeres Therapeutics
N/A
Robert WilsonMadrigal Pharmaceuticals
75
Mala AnandAgilent Technologies
53
HUTCHMED Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchmed China operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 2110 people. HUTCHMED DRC (HCM) is traded on NASDAQ Exchange in USA. It is located in Cheung Kong Center, Hong Kong, Hong Kong and employs 1,988 people. HUTCHMED DRC is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

HUTCHMED DRC Leadership Team

Elected by the shareholders, the HUTCHMED DRC's board of directors comprises two types of representatives: HUTCHMED DRC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HUTCHMED. The board's role is to monitor HUTCHMED DRC's management team and ensure that shareholders' interests are well served. HUTCHMED DRC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HUTCHMED DRC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Eishi Fukumoto, Executive Officer, Chief Director of Research
Tetsuo Katsurayama, Executive Officer, Chief Director of Finance
Genroku Sugiyama, Executive Officer, Director of India Business
Shigeru Endo, Non-Executive Director
Selina Zhang, Senior Resources
Graeme Jack, Independent Non-Executive Director
Masato Tamaki, Executive Officer, CIO, Chief Director of IT Promotion
Koji Sumioka, Executive Officer, Director of Japan Business and Presidentident of Subsidiary
Simon To, Executive Chairman of the Board
Hong Chen, Senior China
Kenji Ohta, Executive Officer, Deputy Chief Director of Sales, Chief Director of Life Cycle Support Business
Paul Carter, Senior Independent Non-Executive Director
Edith Shih, Company Secretary, Non-Executive Director
Yasushi Ochiai, Managing Executive Officer, Chief Director of Sales
Tsutomu Mizutani, Senior Managing Executive Officer, Director of China Business, Director
Takashi Kawamura, Independent Chairman of the Board of Directors
BSE CS, Company Director
Toshihiro Ohno, Executive Officer, Chief Director of Development, Chief Director of PDI
Osamu Okada, Director
ACGI BSc, Ex Chairman
Yukio Arima, Senior Managing Executive Officer, Chief Director of Strategy Planning, Chief Director of Business Administration, Director
Chig Cheng, CFO, Executive Director
Mitsuhiro Tabei, Managing Executive Officer, Chief Director of Marketing, Director
CA BEc, CFO Director
CS CGP, Company Director
Christian Salbaing, Non-Executive Director
Christian Hogg, CEO, Executive Director
Weiguo Su, Executive Director
Karen Atkin, Executive COO
Hisashi Hasegawa, Executive Officer, Chief Human Resource Officer, Chief Director of Human Resources
Kotaro Hirano, Executive Officer, Chief Director of Business Administration
Hiroshi Tokushige, Executive Vice President Representative Executive Officer, Chief Director of Export Management, Leader of C Project, Director
Christopher Nash, Senior Independent Non-Executive Director
Akihiko Hiraoka, Managing Executive Officer, Deputy Chief Director of China Business, General Manager of Subsidiary
Takayoshi Ikeda, Executive Officer, Deputy Chief Director of China Business, General Manager of Subsidiary
Shigeru Azuhata, Independent Director
Kin MBA, Senior Communications
Michifumi Tabuchi, Executive Officer, Director of China Business, General Manager of Subsidiary
Takuro Sato, Director of Legal Affairs
Charles Nixon, Group Counsel
Qingmei Wang, Senior Alliances
Karen Ferrante, Non-Executive Independent Director
Yuichi Tsujimoto, Executive President Representative Executive Officer, Director
Shu Mok, Non-Executive Independent Director
Michael Howell, Independent Non-Executive Director
Christopher Huang, Independent Non-Executive Director
David Ng, Head Strategies
Dan Eldar, Non-Executive Director
Tadashi Motoi, Executive Officer, Deputy Chief Director of Asian & Oceanian Business and Presidentident of Subsidiary
Hideto Mitamura, Independent Director
Weiguo BSc, Chief CEO
Morio Sumiya, Executive Officer, Director of Europe & Middle East Business and Presidentident of Subsidiary

HUTCHMED Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HUTCHMED DRC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether HUTCHMED DRC is a strong investment it is important to analyze HUTCHMED DRC's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact HUTCHMED DRC's future performance. For an informed investment choice regarding HUTCHMED Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HUTCHMED DRC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
To learn how to invest in HUTCHMED Stock, please use our How to Invest in HUTCHMED DRC guide.
Note that the HUTCHMED DRC information on this page should be used as a complementary analysis to other HUTCHMED DRC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for HUTCHMED Stock analysis

When running HUTCHMED DRC's price analysis, check to measure HUTCHMED DRC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HUTCHMED DRC is operating at the current time. Most of HUTCHMED DRC's value examination focuses on studying past and present price action to predict the probability of HUTCHMED DRC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HUTCHMED DRC's price. Additionally, you may evaluate how the addition of HUTCHMED DRC to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Equity Valuation
Check real value of public entities based on technical and fundamental data
Is HUTCHMED DRC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HUTCHMED DRC. If investors know HUTCHMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HUTCHMED DRC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.6
Revenue Per Share
4.93
Quarterly Revenue Growth
0.36
Return On Assets
0.01
Return On Equity
0.1465
The market value of HUTCHMED DRC is measured differently than its book value, which is the value of HUTCHMED that is recorded on the company's balance sheet. Investors also form their own opinion of HUTCHMED DRC's value that differs from its market value or its book value, called intrinsic value, which is HUTCHMED DRC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HUTCHMED DRC's market value can be influenced by many factors that don't directly affect HUTCHMED DRC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HUTCHMED DRC's value and its price as these two are different measures arrived at by different means. Investors typically determine if HUTCHMED DRC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HUTCHMED DRC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.